Sahar Safaei
- Cancer Research top 10%
- MicroRNA in disease regulation 11
- Cancer-related molecular mechanisms research 5
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 7
- CAR-T cell therapy research 4
-
- Immunotherapy and Immune Responses 8
-
- Circular RNAs in diseases 7
- Extracellular vesicles in disease 3
- RNA Interference and Gene Delivery 3
- Co-authors
- Behzad BaradaranAfshin DerakhshaniNicola SilvestrisOronzo BrunettiZahra AsadzadehAhad MokhtarzadehMonireh KhordadmehrRoya Shahbazi
- Cited by
- Cancer ResearchOncologyImmunology
- Journals
- SHILAP Revista de lepidopterología (2 papers)International Journal of Molecular Sciences (1 paper)Frontiers in Immunology (1 paper)
In The Last Decade
Sahar Safaei
29 papers receiving 713 citations
Peers
Comparison fields: 5 of 86
- Cancer Research 185
- Oncology 287
- Immunology 186
- Molecular Biology 349
- Pulmonary and Respiratory Medicine 103
Countries citing papers authored by Sahar Safaei
This map shows the geographic impact of Sahar Safaei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sahar Safaei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sahar Safaei more than expected).
Fields of papers citing papers by Sahar Safaei
This network shows the impact of papers produced by Sahar Safaei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sahar Safaei. The network helps show where Sahar Safaei may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sahar Safaei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 29 | |
| 7 | 2024 | 10 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 7 | |
| 10 | 2023 | 3 | |
| 11 | 2023 | 3 | |
| 12 | 2022 | 4 | |
| 13 | 2022 | 25 | |
| 14 | 2021 | 52 | |
| 15 | 2021 | 17 | |
| 16 | 2021 | 39 | |
| 17 | 2020 | 73 | |
| 18 | 2020 | 127 | |
| 19 | 2020 | 95 | |
| 20 | 2020 | 34 |
About Sahar Safaei
Sahar Safaei is a scholar working on Cancer Research, Immunology and Oncology, having authored 31 papers that have together received 722 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (11 papers), Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), Circular RNAs in diseases (7 papers), Cancer-related molecular mechanisms research (5 papers), CAR-T cell therapy research (4 papers), Extracellular vesicles in disease (3 papers) and RNA Interference and Gene Delivery (3 papers). The work is most often cited by research in Cancer Research (185 citations), Oncology (287 citations) and Immunology (186 citations). Sahar Safaei has collaborated with scholars based in Iran, Denmark and Italy. Frequent co-authors include Behzad Baradaran, Afshin Derakhshani, Nicola Silvestris, Oronzo Brunetti, Zahra Asadzadeh, Ahad Mokhtarzadeh, Monireh Khordadmehr, Roya Shahbazi, Antonella Argentiero and Ali Mohammadi. Their work appears in journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.